FibroGen
FibroGen
FGEN
NASDAQ
0.47
USD
2.17%
About
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF).
Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin.
It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.1M |
| Three Month Average Volume | 54.2M |
| High Low | |
| Fifty-Two Week High | 2.93 USD |
| Fifty-Two Week Low | 0.3333 USD |
| Fifty-Two Week High Date | 12 Feb 2024 |
| Fifty-Two Week Low Date | 10 Nov 2023 |
| Price and Volume | |
| Current Price | 0.3656 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -19.14% |
| Thirteen Week Relative Price Change | -71.53% |
| Twenty-Six Week Relative Price Change | -81.83% |
| Fifty-Two Week Relative Price Change | -69.61% |
| Year-to-Date Relative Price Change | -65.17% |
| Price Change | |
| One Day Price Change | -1.48% |
| Thirteen Week Price Change | -69.53% |
| Twenty-Six Week Price Change | -80.02% |
| Five Day Price Change | -9.08% |
| Fifty-Two Week Price Change | -61.92% |
| Year-to-Date Price Change | -58.75% |
| Month-to-Date Price Change | -32.31% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -2.06708 USD |
| Book Value Per Share (Most Recent Quarter) | -2.31415 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -2.06708 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -2.31415 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.4278 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.51847 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.75761 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.9211 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.70676 USD |
| Normalized (Last Fiscal Year) | -2.83689 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.9211 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.70676 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.9211 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.70676 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.38519 USD |
| Cash Per Share (Most Recent Quarter) | 1.40154 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.84616 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.67381 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.05267 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -65 |
| Cash Flow Revenue (Trailing Twelve Months) | -117 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -98.64% |
| Pretax Margin (Last Fiscal Year) | -194.15% |
| Pretax Margin (5 Year) | -118.93% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 87.24% |
| Gross Margin (Trailing Twelve Months) | 76.65% |
| Gross Margin (5 Year) | 93.52% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -190.74% |
| Operating Margin (Trailing Twelve Months) | -91.86% |
| Operating Margin (5 Year) | -120.47% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -194.16% |
| Net Profit Margin (Trailing Twelve Months) | -98.60% |
| Net Profit Margin (5 Year) | -119.08% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 14.26% |
| Revenue Growth (3 Year) | -7.05% |
| Revenue Change (Trailing Twelve Months) | 33.11% |
| Revenue Per Share Growth | -9.73% |
| Revenue Growth (5 Year) | -5.72% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -20.67% |
| Total Debt (5 Year) | -4.64% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 82.65% |
| EPS Change (Trailing Twelve Months) | 49.63% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -50,839,000 |
| Net Debt (Last Fiscal Year) | -145,745,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 90 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 90 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -317,540,000 |
| Free Cash Flow (Trailing Twelve Months) | -202,994,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -53 |
| Net Interest Coverage (Trailing Twelve Months) | -12 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -55.51% |
| Return on Assets (Trailing Twelve Months) | -42.40% |
| Return on Assets (5 Year) | -30.62% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -88.71% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -119.42% |
| Return on Investment (Trailing Twelve Months) | -89.79% |
| Return on Investment (5 Year) | -42.31% |